Patient monitoring devices

In 2009, the continuous glucose monitoring (CGM) market earned manufacturers $23.5; this is forecast to reach $52.0 million in 2016, according to a new analysis from Frost and Sullivan (F&S). For the study the markets covered by region are Benelux, Germany, France, Italy, Scandinavia, Spain and the United Kingdom.

The primary factor contributing to the growth is the need for an easy-to-use and patient-friendly glucose-monitoring device, F&S reports: The traditional method of monitoring glucose was difficult and inconvenient for patients. Convenient, patient-friendly and affordable devices that facilitate superior therapy management for diabetes are needed, Akanksha Joshi, F&S Senior Research Analyst, points out.

Western Europe’s growing aged population has increased the incidence of fatal diseases (cardiovascular, diabetes, stroke) spurring the need for regular monitoring of patients’ glucose levels and pioneering technology at considerably lower rates.

However, CGM is not reimbursed and the per sensor cost is steep: ‘The traditional finger-stick method offers glucose monitoring solution at much lower rates and is reimbursed all across Europe,’ the F&S analyst points out, but adds: ‘While using a CGM the patient has to buy a starter kit and pay for the disposable sensors year-on-year, making the method of treatment more expensive.’

Nonetheless, collaboration with established local companies will help manufacturers to provide effective services and, at the same time, maintain profit margins, the report continues. ‘Integration of continuous glucose monitors with insulin pumps will pave way for reimbursement options for manufactures, thus reducing the total cost incurred by patients,’ the report reasons. ‘To enable the market participants to include such systems in the reimbursable category, significant clinical evidence suggesting that the device is essential for the patient’s well-being is required. Moreover, when CGM is integrated with insulin pumps, the product will become reimbursable, as it is likely to fall under the medically essential classification of insurance agencies.’

Report details: www.patientmonitoring.frost.com

 

07.07.2010

More on the subject:
Read all latest stories

Related articles

Photo

Article • Diabetology 4.0

Emerging technologies for diabetes care

This overview introduces connected and continuous glucose sensing technologies, smart insulin delivery systems and more innovations that help patients and doctors monitor and manage glucose levels…

Photo

News • Multi-tasking

Wearable monitors glucose, alcohol, and lactate

Engineers have developed a prototype of a wearable that can continuously monitor several health stats—glucose, alcohol, and lactate levels—simultaneously in real-time.

Photo

Interview • Tectales

Humanising wearable health technologies

Designer Leah Heiss considers her work as creating “emotional technologies”, i.e. wearable devices based on human-centred design principles. For her, empathy is everything!

Related products

Fujifilm Wako – Autokit Total Ketone Bodies Assay

Clinical Chemistry

Fujifilm Wako – Autokit Total Ketone Bodies Assay

FUJIFILM Wako Chemicals Europe GmbH
Beckman Coulter – Psychiatry Antipsychotic Assays

Clinical Chemistry

Beckman Coulter – Psychiatry Antipsychotic Assays

Beckman Coulter Diagnostics
Guerbet · Dose&Care

Dose Management Systems

Guerbet · Dose&Care

Guerbet
Nova Biomedical – StatStrip Glucose/Ketone*

Blood Glucose

Nova Biomedical – StatStrip Glucose/Ketone*

Nova Biomedical Corporation
Subscribe to Newsletter